Goldman Sachs’s ECHO THERAPEUTICS, INC. NEW COMMON STOCK (DE) ECTE Stock Holding History

Goldman Sachs’s Portfolio ECTE Stock Details ECTE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-21,728	Closed	-$28K	–	7461
2016 Q1	$28K	Buy	21,728 +6,471	+42%	+$7.71K	﹤0.01%	6652
2015 Q4	$22K	Hold	15,257	–	–	﹤0.01%	6830
2015 Q3	$24K	Sell	15,257 -3,159	-17%	-$5.03K	﹤0.01%	6994
2015 Q2	$31K	Buy	18,416 +3,439	+23%	+$5.75K	﹤0.01%	6999
2015 Q1	$32K	Buy	14,977 +143	+1%	+$335	﹤0.01%	6817
2014 Q4	$20K	Buy	+14,834	New	+$12.9K	﹤0.01%	6991

Other funds holding ECTE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $74.2B AUM 21.09% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

AIM

Acrospire Investment Management Chicago, Illinois $33K AUM 23.36% 1-Year Est. Return

Goldman Sachs's ECTE Position: Q2 2016 in Review

Goldman Sachs sold out of ECHO THERAPEUTICS, INC. NEW COMMON STOCK (DE) (ECTE) in Q2 2016, closing a stake of 21,728 shares — an estimated $28K sold.

Goldman Sachs first reported a position in ECTE in Q4 2014 and held it in 6 quarters. The position peaked at $32K in Q1 2015. 18 funds tracked by Wall St. Rank hold ECTE as of Q2 2016.

Goldman Sachs reported no remaining ECHO THERAPEUTICS, INC. NEW COMMON STOCK (DE) position as of Q2 2016 after selling out during the quarter.
Goldman Sachs sold 21,728 ECHO THERAPEUTICS, INC. NEW COMMON STOCK (DE) shares in Q2 2016, an estimated $28K.
Goldman Sachs first reported a position in ECHO THERAPEUTICS, INC. NEW COMMON STOCK (DE) in Q4 2014 and held it in 6 quarters.
Goldman Sachs's ECHO THERAPEUTICS, INC. NEW COMMON STOCK (DE) position peaked at $32K in Q1 2015.
18 funds tracked by Wall St. Rank held ECHO THERAPEUTICS, INC. NEW COMMON STOCK (DE) as of Q2 2016.

Based on Goldman Sachs's 13F filing for Q2 2016, filed 15 Aug 2016.